ArticleCell death & disease2026
The chaperonin TRiC component Cct3 is required for axonal transport, myelination, and neuromuscular junction refinement.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CCT3 Enhances Lung Adenocarcinoma Progression by Promoting p53 Ubiquitination and Degradation.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
TRiCopathies are recently discovered neurodevelopmental diseases caused by pathogenic variants in components of the chaperonin tailless complex polypeptide 1 ring complex (TRiC). Composed of chaperonin containing TCP1 subunits 1-8 (CCT1-8), TRiC acts as a chaperone that is required for folding of 10% of proteome, including actin and tubulin. Patients with TRiCopathies display variable combinations of cognitive impairment, epilepsy, polymicrogyria, white matter reduction, cerebellar hypoplasia and alterations in the peripheral neuromuscular system. Here, we aimed at better understanding the pathophysiological role of Cct3 in neurodevelopment, particularly in myelin formation and the neuromuscular system using zebrafish as a model system. We have generated two CRISPR/Cas9 loss-of-function alleles of the orthologous zebrafish cct3 gene. By combining these alleles with transgenic lines and immunostainings we visualized different cell types and subcellular structures in the nervous system by confocal microscopy. Furthermore, we performed electron microscopy to examine zebrafish in comparison to human patient-derived tissue. We demonstrated that cct3 mutant zebrafish fail to form normal myelin sheaths. This was associated with early apoptotic death of neural crest-derived Schwann cells, which were particularly vulnerable to loss of Cct3 function. In line with the observations in patients, developmental refinement of neuromuscular junctions (NMJ) required Cct3. Furthermore, we observed profound cytoskeletal alterations, in particular of tubulin and microtubules as well as severely disturbed microtubule-dependent axonal transport of organelles in peripheral motor axons. Cct3 displays an essential role in myelination, survival of neural crest-derived cells, NMJ refinement, tubulin and microtubule biology as well as axonal transport. Given that axonal transport is essential for transport of axon-glial and signaling factors shaping the NMJ, we speculate that the essential role of Cct3 in axonal transport is a common denominator for the observed phenotypes. These data enhance our understanding of the conserved role of Cct3/TRiC in the developing nervous system and the pathophysiological mechanisms in TRiCopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.